Clinical Trial Site Readiness

A clinical trial site is ready when it can conduct the approved protocol safely, consistently, and within the agreed operating model. Readiness is not established by an optimistic feasibility response or by completing an initiation visit. It is demonstrated through evidence that the investigator, staff, facilities, systems, participant pathway, and supporting services can meet study requirements.

Test feasibility with local evidence

Feasibility should begin with the protocol’s critical-to-quality factors. These are the elements that are fundamental to participant protection, the reliability and interpretability of results, and decisions based on those results. For a specific site, this means testing the actual patient pathway, eligibility criteria, visit burden, endpoint procedures, safety risks, investigational-product requirements, and data flow.

Recruitment projections should be supported by recent, auditable data and adjusted for competing studies, referral leakage, seasonal variation, diagnostic capacity, screen-failure assumptions, and expected retention. The team should ask whether potentially eligible people can be identified ethically, approached appropriately, consented in a language they understand, and supported through the full visit schedule.

Confirm people, time, and delegation

The principal investigator must have sufficient time and control to supervise the trial. A readiness review should map each protocol activity to a qualified person, identify vacancies or competing commitments, and confirm backup coverage for critical roles. Curriculum vitae, professional licences, GCP and protocol training, delegation records, and signature records should be current before activity begins.

Training should be role-specific and assessed for understanding. A laboratory technologist needs different protocol details from a pharmacist or recruitment officer. Scenario-based rehearsal is especially useful for consent, randomisation, safety escalation, protocol deviations, specimen handling, temperature excursions, and emergency unblinding.

Verify facilities and supporting services

Readiness should cover consultation and consent space, pharmacy controls, secure record storage, calibrated equipment, laboratory certification and reference ranges, sample processing, cold-chain capacity, backup power, waste handling, emergency care, and transport. External laboratories, couriers, imaging centres, home-health providers, or referral hospitals should be qualified where their work affects participant safety or trial data.

For digital or decentralised elements, the site should verify connectivity, device availability, privacy, user support, data transfer, and procedures for technology failure. The operating model should remain usable for participants who have limited digital access.

Close approval and document gaps

No study activity should begin without the approvals required for that activity. In Nigeria, clinical trials require written authorisation and should follow the approved protocol, GCP, and agency requirements. Before activation, the site should have only current approved versions in use. Consent materials, recruitment content, safety information, laboratory manuals, pharmacy instructions, and source templates should agree with the protocol.

A controlled essential-records index should identify the owner and location of each record. This is especially important where the study is supported by multiple service providers, external laboratories, or remote data systems.

Use an activation decision, not a date

Activation should depend on objective release criteria. Open actions should be classified by their potential effect on participants, data, or supply. A site may be activated only when critical issues are closed and remaining noncritical actions have owners and due dates.

A useful readiness review ends with four outputs: an evidence-backed recruitment forecast; a resource and facility confirmation; a risk register with controls; and a signed activation recommendation. Early post-activation review of consent quality, screening, deviations, safety reporting, investigational-product control, and data timeliness then tests whether planned readiness has translated into reliable performance.

MedNova supports clinical development, regulatory consulting, pharmacovigilance, medical information, and resource planning for sponsors and investigators who need practical support across feasibility, start-up, activation, and study delivery.

References

1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH E6(R3): Guideline for good clinical practice. Published January 6, 2025. Accessed July 18, 2026. https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf
2. National Agency for Food and Drug Administration and Control. Good Clinical Practice Guidelines 2025. Effective May 5, 2025. Accessed July 18, 2026. https://nafdac.gov.ng/wp-content/uploads/Files/Resources/Guidelines/ICH_Guidelines/NAFDAC-Good-Clinical-Practice-GCP-Guidelines-2025.pdf
3. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH E8(R1): General considerations for clinical studies. Published October 6, 2021. Accessed July 18, 2026. https://database.ich.org/sites/default/files/E8-R1_Guideline_Step4_2022_0204%20%281%29.pdf
4. National Agency for Food and Drug Administration and Control. Clinical trial regulation. Accessed July 18, 2026. https://nafdac.gov.ng/drugs/clinical-trial-regulation/
5. National Agency for Food and Drug Administration and Control. Guidelines for clinical trial application in Nigeria 2024. Effective November 19, 2024. Accessed July 18, 2026. https://nafdac.gov.ng/wp-content/uploads/Files/Resources/Guidelines/Clinical_Guidelines_2024/Guidelines-for-Clinical-Trial-Application-in-Nigeria.pdf